Oxford BioMedica (OTCMKTS:OXBDF – Get Free Report) gapped up before the market opened on Tuesday . The stock had previously closed at $5.9966, but opened at $6.61. Oxford BioMedica shares last traded at $6.61, with a volume of 145 shares changing hands.
Wall Street Analysts Forecast Growth
Separately, Zacks Research raised Oxford BioMedica to a “hold” rating in a report on Wednesday, July 22nd. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock has an average rating of “Hold”.
Get Our Latest Research Report on Oxford BioMedica
Oxford BioMedica Stock Up 10.2%
Oxford BioMedica Company Profile
Oxford BioMedica plc is a United Kingdom-based contract development and manufacturing organization (CDMO) focused on cell and gene therapies. The company helps biotechnology and pharmaceutical customers develop, test, and manufacture advanced therapies, with expertise in viral-vector technologies used to deliver genetic material into cells.
Its services include process and analytical development, clinical and commercial manufacturing, quality testing, regulatory support, and related research services.
Featured Articles
- Five stocks we like better than Oxford BioMedica
- IonQ’s AI Breakthrough Looks Big—But Can It Drive Revenue?
- Broadcom CEO Holds $350B Outlook Strong Amid Calls to Slow Froniter AI Development
- Microsoft’s 8% Dividend Hike: Confidence Signal or Distraction From Capex Math?
- Paramount Skydance Clears a Major Warner Bros. Discovery Hurdle—Here’s What Comes Next
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.
